BRAF and metastatic colorectal cancer: In summary, patients with wild-type RAS/BRAF left-sided metastatic colorectal cancer undergoing FOLFOXIRI combined with anti-EGFR therapy could achieve a high ORR and R0 resection rate; this regimen is suitable for patients with an optimal physical status score and an urgent need for tumor regression in conversion therapy.